NCT03321968View on ClinicalTrials.gov

Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,202

Participants

Timeline

Start Date

September 29, 2017

Primary Completion Date

December 1, 2017

Study Completion Date

December 1, 2017

Conditions
Virus DiseasesRNA Virus InfectionsRespiratory Tract InfectionsRespiratory Tract DiseaseInfluenza
Interventions
BIOLOGICAL

Quadrivalent VLP Influenza Vaccine

Single dose of 30 µg/strain Quadrivalent VLP Influenza Vaccine

Trial Locations (10)

Unknown

Site 205, Halifax

Site 208, Burlington

Site 207, Guelph

Site 202, Toronto

Site 204, Chicoutimi

Site 203, Gatineau

Site 201, Lévis

Site 209, Pointe-Claire

Site 206, Toronto

Site 210, Victoriaville

Sponsors

Lead Sponsor

Medicago
All Listed Sponsors
lead

Medicago

INDUSTRY

NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter